V451 was a COVID-19 vaccine candidate developed by the University of Queensland and the Australian pharmaceutical company CSL Limited. The vaccine candidate...

adenovirus type-5 (Ad5) are being used by Ad5-nCoV, ImmunityBio and UQ-CSL V451. The Gam-COVID-Vac (aka Sputnik-V) product is innovative because an Ad26...

the Australian government to supply the University of Queensland vaccine (V451) and to manufacture (with AstraZeneca) the Oxford University vaccine (AZD1222)...

approved for use as a booster vaccine in the European Union in March 2023. The V451 vaccine was in clinical trials that were terminated after it was found that...

COVID-19 vaccine Oxford–AstraZeneca COVID-19 vaccine Sputnik V COVID-19 vaccine V451 vaccine "BioNTech 2023 Annual Report (Form 20-F)". U.S. Securities and Exchange...

Nanocovax ReCOV Sanofi–GSK S-268019 SCB-2019 SCTV01C Skycovione UB-612 V-01 V451 (terminated) Vabiotech West China Hospital Zhongyianke Biotech–Liaoning Maokangyuan...

Royal Australian Institute of Architects. Architect's Housing Service Plan V451 Model 1300 Renovate : architectural concepts for rejuvenating houses and...

Archived from the original on 11 October 2020. Retrieved 4 August 2020. "UQ-CSL V451 Vaccine". precisionvaccinations.com. Retrieved 11 December 2020. "Dose Ranging...

to have experienced a contraction from 2019 figures. On 11 December, the V451 vaccine being developed at the University of Queensland was abandoned after...

2020-12-11. Retrieved 2020-12-11. "BRIEF-CSL Says Will Not Progress UQ-CSL V451 COVID-19 Vaccine Candidate To Phase 2/3 Clinical Trials". Reuters. 2020-12-10...